AR059258A1 - METHODS TO INTERFER WITH THE GASTRIC ACID SECRETION INDUCED BY GLUCOCORTICOIDS - Google Patents

METHODS TO INTERFER WITH THE GASTRIC ACID SECRETION INDUCED BY GLUCOCORTICOIDS

Info

Publication number
AR059258A1
AR059258A1 ARP070100405A ARP070100405A AR059258A1 AR 059258 A1 AR059258 A1 AR 059258A1 AR P070100405 A ARP070100405 A AR P070100405A AR P070100405 A ARP070100405 A AR P070100405A AR 059258 A1 AR059258 A1 AR 059258A1
Authority
AR
Argentina
Prior art keywords
gastric acid
glucocorticoids
interfer
methods
glucocorticoid
Prior art date
Application number
ARP070100405A
Other languages
Spanish (es)
Inventor
Florian Lang
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR059258A1 publication Critical patent/AR059258A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/062—Gastritis or peptic ulcer disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un método para alterar la secrecion de ácido gástrico inducida por glucocorticoides, que comprende poner en contacto células que expresan quinasa inducible por glucocorticoides del suero (SGK) con una sustancia que modula dicha quinasa inducible por glucocorticoides. Además, la presente se relaciona con el diagnostico y la identificacion de compuestos que pueden ser agonistas o antagonistas que son potencialmente utiles en la terapia de la secrecion patologica de ácido gástrico. Reivindicacion 1: Un método para alterar la secrecion de ácido gástrico que comprende poner en contacto células que expresan SGK1, SGK2 o SGK3 con una sustancia que modula las quinasas inducibles por glucocorticoides.A method for altering the secretion of gastric acid induced by glucocorticoids, which comprises contacting cells that express serum glucocorticoid-inducible kinase (SGK) with a substance that modulates said glucocorticoid-inducible kinase. In addition, this relates to the diagnosis and identification of compounds that may be agonists or antagonists that are potentially useful in the therapy of the pathological secretion of gastric acid. Claim 1: A method for altering gastric acid secretion comprising contacting cells expressing SGK1, SGK2 or SGK3 with a substance that modulates glucocorticoid inducible kinases.

ARP070100405A 2006-01-31 2007-01-31 METHODS TO INTERFER WITH THE GASTRIC ACID SECRETION INDUCED BY GLUCOCORTICOIDS AR059258A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06001934 2006-01-31

Publications (1)

Publication Number Publication Date
AR059258A1 true AR059258A1 (en) 2008-03-19

Family

ID=38006823

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100405A AR059258A1 (en) 2006-01-31 2007-01-31 METHODS TO INTERFER WITH THE GASTRIC ACID SECRETION INDUCED BY GLUCOCORTICOIDS

Country Status (7)

Country Link
EP (1) EP1979747A1 (en)
JP (1) JP2009531020A (en)
AR (1) AR059258A1 (en)
AU (1) AU2007211655A1 (en)
CA (1) CA2641325A1 (en)
IL (1) IL193081A0 (en)
WO (1) WO2007087985A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210008193A (en) * 2019-07-10 2021-01-21 한양대학교 산학협력단 Use of Sgk1 inhibitor for treating inflammatory neurologic disorders
EP4232016A4 (en) * 2020-10-26 2024-04-17 Univ Of North Dakota Use of small molecule fak activators to promote mucosal healing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10346913A1 (en) * 2003-10-09 2005-05-04 Merck Patent Gmbh acylhydrazone
JP2007527876A (en) * 2004-03-08 2007-10-04 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Method for modifying insulin secretion
RU2006135653A (en) * 2004-03-11 2008-04-20 Мерк Патент ГмбХ (DE) METHODS Preventing Fibrosis
CA2559136A1 (en) * 2004-03-11 2005-10-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases
US20090136920A1 (en) * 2004-04-30 2009-05-28 Stefan Golz Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)

Also Published As

Publication number Publication date
IL193081A0 (en) 2009-02-11
JP2009531020A (en) 2009-09-03
WO2007087985A1 (en) 2007-08-09
EP1979747A1 (en) 2008-10-15
CA2641325A1 (en) 2007-08-09
AU2007211655A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
Tomasek et al. Whole animal knockout of smooth muscle alpha‐actin does not alter excisional wound healing or the fibroblast‐to‐myofibroblast transition
BR112019006706A2 (en) improved methods for assessing gfap status in patient samples
BR112015022934A2 (en) neuroactive steroids, compositions, and use thereof
BR112014016313A2 (en) Accurate analyte measurements for electrochemical test strip based on detected physical characteristic (s) of sample containing analyte and derived biosensor parameters
BRPI0518307A2 (en) Method and composition for treating a subject having a cancer, kit, pharmaceutical composition, method for impregnating or loading an implantable drug release device, implantable drug release device, method for assessing an individual's response to a cancer. treatment using a tlr3 agonist or selecting an individual having a cancer responsive to treatment using a tlr3 agonist, complex, method for determining whether a test compound is useful for cancer treatment, and use of a tlr3 agonist
BR112013008364A2 (en) porous mass smoking devices having a carbon particle charge and an encapsulated pressure drop
MY192493A (en) Urinalysis device and dry reagent for quantitative urinalysis
BR112014000965B8 (en) METHOD, APPLIANCE AND NON-TRAINER STORAGE MEDIA
EP4239332A3 (en) Substance-marking patch, and method and apparatus for tissue diagnosis using same
WO2014036495A3 (en) Diagnostic assays and kits for detection of folate receptor 1
BR112016014756A8 (en) sealant formulation comprising fibrinogen and zymogens, their method of manufacture, container and use
WO2008122789A3 (en) Methods for modulating lrrk2
WO2012056236A3 (en) Analytical methods and arrays for use in the identification of agents inducing sensitization in human skin
WO2007092864A3 (en) Calibration arrangement for breath testing equipment
GB201207297D0 (en) Analytical methods and arrays for use in the same
NZ630026A (en) Inhibition of the glycine cleavage system for treatment of cancer
MX2015014892A (en) Method for a cell-based drug screening assay and the use thereof.
WO2015011282A8 (en) Method for identifying modulators of bcrp/abcg2-mediated atp release and use of said modulators for treating diseases
BR112017006315A2 (en) therapeutic agent, use of a therapeutic agent, in vitro methods for determining whether a subject with melanoma has a higher risk of metastasis, determining a treatment regimen for a subject suffering from melanoma, treating a subject suffering from melanoma, in vitro test to predict increased risk of metastasis and kits
BR112015022926A8 (en) implant testing system
HK1099810A1 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
WO2015189591A3 (en) Method and arrays for use in diagnosing early breast cancer
BR112018016394A2 (en) device and process for isolating whole blood nucleic acids
AU2018275891A1 (en) Articles of manufacture and methods related to toxicity associated with cell therapy
AR059258A1 (en) METHODS TO INTERFER WITH THE GASTRIC ACID SECRETION INDUCED BY GLUCOCORTICOIDS

Legal Events

Date Code Title Description
FB Suspension of granting procedure